Form Heading

Tag: China

Page 16 of 18 1 15 16 17 18

FEATURED NEWS

  • Myomo’s Medical Device Could Help COVID-19 Survivors
    With sales growing at 50%-60%, Myomo Inc. (MYO) trades at 1x forward sales. I don’t believe that the undervaluation of the stock is justified. In addition, the company’s medical device could be very …
  • Tesoro Enterprises, Inc. To Start HUMBL Studios
    Shareholders of Tesoro Enterprises, Inc. (TSNP) are celebrating the most recent stock price dynamics. From December 17, 2020, the share price has increased more than 100%. The fact that the company …
  • fish covered with necklace and stylish jacketHepion Pharmaceuticals Inc $HEPA: Crazy Amount Of Cash In Hand

    Balance Sheet As Of 2020-12-31

    HEPA shows $40 million in cash and cash equivalents. In my experience, the company has a good amount of cash to conduct additional R&D and increase its marketing efforts. Moreover, Hepion Pharmaceuticals Inc has positive working capital, which market participants will like. It means that HEPA can cover its short-term liabilities when they come due. HEPA's short term debt is less significant than the company's cash and cash equivalents. In my experience, Hepion Pharmaceuticals Inc may not have to worry about any liquidity risk. Moreover, the price to book value is below 1. 5x, which means that HEPA is undervalued. Hepion Pharmaceuticals Inc has $48 million in total assets, and $8 million in total liabilities. In my experience, HEPA is cheap. Additionally, notice that the cash per share is equal to $4, and the stock price is $1. 91. HEPA's debt to equity ratio is below 2x. In short, the debt level appears to be under control. Note that Hepion Pharmaceuticals Inc reports cash and cash equivalents of $40 million, and net debt of $-40 million. With regards to the EV/EBITDA, Hepion Pharmaceuticals Inc trades at 1. I feel that market participants will most likely appreciate this low figure. …
  • Ballard Power (NASDAQ: BLDP) Is Set To Decline
    We don’t expect the share price to increase a lot from $8. Ballard trades at more than 15x 2019 sales. Yes, the company’s revenue growth is impressive. However, the current valuation is …

Login to your account below

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.